Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626000 | 0.88 | DNM1 (0.46) | FDPSSMPD1DNM1TSHRMEN1 | |
| SCHEMBL27656728 | 0.88 | DNM1 (0.46) | FDPSSMPD1DNM1TSHRMEN1 | |
| SCHEMBL37594 | 0.88 | DNM1 (0.46) | FDPSSMPD1DNM1TSHRMEN1 | |
| SCHEMBL3625436 | 0.88 | DNM1 (0.46) | FDPSSMPD1DNM1TSHRMEN1 | |
| SCHEMBL3627595 | 0.88 | DNM1 (0.46) | FDPSSMPD1DNM1TSHRMEN1 | |
| SCHEMBL14012811 | 0.88 | DNM1 (0.46) | FDPSSMPD1DNM1TSHRMEN1 | |
| SCHEMBL41716 | 0.88 | DNM1 (0.46) | FDPSSMPD1DNM1TSHRMEN1 | |
| SCHEMBL17359326 | 0.88 | DNM1 (0.46) | FDPSSMPD1DNM1TSHRMEN1 | |
| SCHEMBL7483482 | 0.85 | CYP2D6 (0.47) | FDPSSMPD1DNM1TSHRMEN1 | |
| SCHEMBL24375706 | 0.84 | DNM1 (0.42) | FDPSSMPD1DNM1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202344-B2 | Aryl substituted indoles and the use thereof | PURDUE PHARMA L.P. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | PURDUE PHARMA L.P. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180022699-A1 | ARYL SUBSTITUTED INDOLES AND THE USE THEREOF | TRPC5, TRPV5, TRPV1 | FDPS 1593/4885SMPD1 1350/4885DNM1 3596/4885 |
| US-10202344-B2 | Aryl substituted indoles and the use thereof | TRPC5, TRPV5, TRPV1 | FDPS 1593/4885SMPD1 1350/4885DNM1 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.